Executive management from healthcare communications agencies and networks weigh in on industry topics ranging from the COVID-19 pandemic to diversity, equity and inclusion.
Med Ad News’ 2021 Company of the Year Pfizer has led the global war against the COVID-19 pandemic with the vaccine Comirnaty in partnership with BioNTech. To find out about some of the other significant products and pipeline assets in Pfizer’s arsenal, Med Ad News talked to Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical.
As healthcare companies continue to refine and expand methods of achieving diversity, equity and inclusion, DE&I leaders know their efforts are not a sprint, but part of an ongoing journey.
The Medical Advertising Hall of Fame honored 2019 inductees Carol DiSanto and Charlene Prounis on Feb. 7th at The Pierre in New York City.
The threatened “pharma marketing tax” may be back in play during 2019, at both the federal and state levels.
The U.S. Department of Health and Human Services (HHS) is considering proposing a plan that has many moving parts, one of which could potentially take the price that Medicare pays out to providers for Medicare Part B drugs and turn it on its head.
The talent and tenacity of immigrants can help drive the life sciences industry into the future, if we have the will and the wisdom to encourage it.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
Emboldened by 2017’s back-to-back FDA approvals of the first drugs that use genetically engineered patient immune cells – Kymriah (tisagenlecleucel) to treat leukemia and Yescarta (axicabtagene ciloleucel) to combat large-B-cell lymphomas – immunotherapy researchers are continuing to revolutionizing cancer treatment. But uneven patient response rates and the side effects often associated with immunotherapies are putting high priority on accurately identifying which patients would benefit most from particular treatment options.